Abbott To Co-Promote AstraZeneca’s Crestor

Abbott and AstraZeneca have entered into an agreement for Abbott to promote AZ’s cholesterol drug Crestor. Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote the drug alongside AZ in the U.S., excluding Puerto Rico. Financial terms were not disclosed.
   
This agreement is the second collaboration between the two companies. In 2006, they announced an agreement to develop a fixed-dose combination of the active ingredients in Abbott’s investigational TriLipix and AZ’s Crestor, with plans to submit a NDA to FDA in 2009. An NDA for TriLipix for use as monotherapy and in combination with statins has been submitted to the FDA and is currently under review.
   
“This agreement will allow AstraZeneca to increase share of voice for Crestor among physicians whose patients may benefit from this therapy. We see this as a good fit for both companies as this agreement allows us to leverage Abbott’s established presence in the dyslipidemia space,” said Mike Tilton, vice president of Primary Care, AstraZeneca.